Keyphrases
Cyclooxygenase-1 (COX-1)
84%
Indomethacin
80%
Rat Knee Joint
74%
Protease-activated Receptor 2 (PAR2)
74%
Cyclooxygenase-2
69%
Arthritis
59%
Serum-free Medium
56%
Growth Factors
56%
Nitrergic System
46%
Low Serum
46%
Growth Characteristics
46%
NIH3T3
46%
Cyclooxygenase-1/2
44%
Carrageenan
43%
Endothelial Cells
42%
Hyperemia
42%
Plasminogen Activator inhibitor-1 (PAI-1)
37%
Acute Inflammatory
37%
Primary Culture
37%
Pathophysiological Basis
37%
Dual Inhibition
37%
J774 Macrophages
37%
Human Umbilical Vein Endothelial Cells (HUVECs)
37%
3T3 Cells
37%
Basic Fibroblast Growth Factor (bFGF)
37%
Cell-based Assay
37%
Large T-antigen (LTAg)
37%
Secreted Alkaline Phosphatase
37%
Electrochemical Detection
37%
Tissue Plasminogen Activator (t-PA)
37%
Cell Aging
37%
Umbilical Cord
37%
Insulin
37%
L-NAME
37%
Antagonism
37%
Prostanoids
37%
Joint Inflammation
37%
Therapeutic Promises
37%
Perfusion
37%
Insulin-like Growth Factor 2 (IGF2)
37%
Insulin-like Growth factor-1
37%
Joint Swelling
35%
Prostaglandins
35%
Transfected Cells
34%
Enzyme Activity
31%
Inducible Nitric Oxide Synthase
28%
Inflammation
27%
Laser Doppler Imaging
26%
Simian Virus 40 (SV40)
25%
Endothelial Markers
25%
Medicine and Dentistry
Cyclooxygenase 1
74%
Indometacin
62%
Prostaglandin Synthase
46%
Knee Joint
43%
Analysis of Variance
43%
Prostaglandin
40%
Messenger RNA
40%
Hyperaemia
37%
3T3 Cells
37%
Prothrombin
37%
Carrageenan
37%
Somatomedin
37%
Proteinase Activated Receptor 2
37%
Fibrinogen
37%
Arthritis
37%
Cyclooxygenase 2
37%
Vascular Resistance
34%
Urinary System
28%
4 [5 (4 Chlorophenyl) 3 Trifluoromethyl 1h Pyrazol 1 Yl]benzenesulfonamide
28%
Growth Factor
25%
Reverse Transcription Polymerase Chain Reaction
25%
Blood Flow
21%
Intravenous Drug Administration
21%
Inducible Nitric Oxide Synthase
18%
Metabolite
18%
Nitric Oxide
18%
Joint Swelling
18%
Transfected Cell Line
12%
Blotting
12%
Copurification
12%
Morphology
12%
Cell Culture
12%
Monoclonal Antibody
9%
Disease Modifying Antirheumatic Drug
9%
Biological Therapy
9%
Piperazine
9%
TNF Inhibitor
9%
Prostaglandin Synthase Inhibitor
9%
Receptor Upregulation
9%
Antiserum
9%
Serine Proteinase Inhibitor
9%
Infusion
9%
Joint Injection
9%
Cyclooxygenase 2 Inhibitor
9%
Antiinflammatory Agent
9%
Serositis
9%
Immunoblotting
9%
Upregulation
9%
Tryptase
9%
Serine Proteinase
9%
Pharmacology, Toxicology and Pharmaceutical Science
Indometacin
100%
Cyclooxygenase 1
74%
Prostaglandin Synthase
59%
Prostaglandin
53%
Cyclooxygenase 2
49%
Arthritis
49%
Inflammation
40%
Messenger RNA
40%
Hyperaemia
37%
Carrageenan
37%
Proteinase Activated Receptor 2
37%
Prostanoid
37%
Nitric Oxide
31%
4 [5 (4 Chlorophenyl) 3 Trifluoromethyl 1h Pyrazol 1 Yl]benzenesulfonamide
28%
RNA Directed DNA Polymerase
25%
Rheumatoid Arthritis
21%
Inflammatory Arthritis
21%
Inducible Nitric Oxide Synthase
18%
Joint Swelling
18%
Receptor
18%
Nitric Oxide Synthase
12%
Anti-Inflammatory Drug
12%
Tumor Necrosis Factor
12%
COX-2 Inhibitor
9%
Prostaglandin Synthase Inhibitor
9%
Tryptase
9%
Disease Modifying Antirheumatic Drug
9%
Antiserum
9%
Piperazine
9%
Tumor Necrosis Factor Inhibitor
9%
Monoclonal Antibody
9%
Antiinflammatory Agent
9%
Small Interfering RNA
9%
Knockout Mouse
9%
Serine Proteinase Inhibitor
9%
Serine Proteinase
9%
Western Blot
9%
